Literature DB >> 4706203

The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma.

R D Leeper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4706203     DOI： 10.1210/jcem-36-6-1143

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  20 in total

Review 1.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

Review 2.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 3.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

Review 4.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

5.  The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.

Authors:  Frederik A Verburg; Markus Luster; Luca Giovanella; Michael Lassmann; Carlo Chiesa; Nicolas Chouin; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-16       Impact factor: 9.236

6.  The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.

Authors:  C Chiesa; K Sjogreen Gleisner; G Flux; J Gear; S Walrand; K Bacher; U Eberlein; E P Visser; N Chouin; M Ljungberg; M Bardiès; M Lassmann; L Strigari; M W Konijnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-24       Impact factor: 9.236

7.  The value of intraoperative scintigraphy as a routine procedure in thyroid carcinoma.

Authors:  S Lennquist; J Persliden; S Smeds
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

Review 8.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

9.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

10.  Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?

Authors:  C A Proye; D H Dromer; B M Carnaille; A J Gontier; A Goropoulos; P Carpentier; J Lefebvre; M Decoulx; J L Wemeau; P Fossati
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.